142 related articles for article (PubMed ID: 25208348)
1. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
[TBL] [Abstract][Full Text] [Related]
2. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Delgado-Goñi T; Ortega-Martorell S; Ciezka M; Olier I; Candiota AP; Julià-Sapé M; Fernández F; Pumarola M; Lisboa PJ; Arús C
NMR Biomed; 2016 Jun; 29(6):732-43. PubMed ID: 27061401
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
[TBL] [Abstract][Full Text] [Related]
4. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Wu S; Calero-Pérez P; Arús C; Candiota AP
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
[TBL] [Abstract][Full Text] [Related]
6. Improving the classification of brain tumors in mice with perturbation enhanced (PE)-MRSI.
Simões RV; Ortega-Martorell S; Delgado-Goñi T; Le Fur Y; Pumarola M; Candiota AP; Martín J; Stoyanova R; Cozzone PJ; Julià-Sapé M; Arús C
Integr Biol (Camb); 2012 Feb; 4(2):183-91. PubMed ID: 22193155
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F
J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679
[TBL] [Abstract][Full Text] [Related]
8. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Park I; Bok R; Ozawa T; Phillips JJ; James CD; Vigneron DB; Ronen SM; Nelson SJ
J Magn Reson Imaging; 2011 Jun; 33(6):1284-90. PubMed ID: 21590996
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors.
Delgado-Goñi T; Martín-Sitjar J; Simões RV; Acosta M; Lope-Piedrafita S; Arús C
NMR Biomed; 2013 Feb; 26(2):173-84. PubMed ID: 22814967
[TBL] [Abstract][Full Text] [Related]
10. Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Stamatakos GS; Antipas VP; Uzunoglu NK
Comput Biol Med; 2006 Nov; 36(11):1216-34. PubMed ID: 16207487
[TBL] [Abstract][Full Text] [Related]
11. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Wei KC; Chu PC; Wang HY; Huang CY; Chen PY; Tsai HC; Lu YJ; Lee PY; Tseng IC; Feng LY; Hsu PW; Yen TC; Liu HL
PLoS One; 2013; 8(3):e58995. PubMed ID: 23527068
[TBL] [Abstract][Full Text] [Related]
12. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
14. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Radoul M; Chaumeil MM; Eriksson P; Wang AS; Phillips JJ; Ronen SM
Mol Cancer Ther; 2016 May; 15(5):1113-22. PubMed ID: 26883274
[TBL] [Abstract][Full Text] [Related]
15. Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Miller K; Dixit S; Bredlau AL; Moore A; McKinnon E; Broome AM
Nanomedicine (Lond); 2016 Mar; 11(6):581-95. PubMed ID: 27003178
[TBL] [Abstract][Full Text] [Related]
16. Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Sheehan J; Cifarelli CP; Dassoulas K; Olson C; Rainey J; Han S
J Neurosurg; 2010 Aug; 113(2):234-9. PubMed ID: 20001586
[TBL] [Abstract][Full Text] [Related]
17. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
[TBL] [Abstract][Full Text] [Related]
18. Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Poelen J; Prick MJ; Jeuken JW; Wesseling P; Bernsen HJ
Acta Neurol Belg; 2009 Sep; 109(3):238-42. PubMed ID: 19902821
[TBL] [Abstract][Full Text] [Related]
19. Monitoring the effects of BCNU chemotherapy Wafers (Gliadel) in glioblastoma multiforme with proton magnetic resonance spectroscopic imaging at 3.0 Tesla.
Dyke JP; Sanelli PC; Voss HU; Serventi JV; Stieg PE; Schwartz TH; Ballon D; Shungu DC; Pannullo SC
J Neurooncol; 2007 Mar; 82(1):103-10. PubMed ID: 17031552
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant temozolomide: how long and how much?
Franceschi E; Tosoni A; Brandes AA
Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
[No Abstract] [Full Text] [Related]
[Next] [New Search]
